RxDoctor Payments Data

Kaushik Patel, MD

Internal Medicine · Pittsburgh, PANPI 1649256843

Payments from drug & device makers

$13,189in general payments, 2019–2025

Across 784 payments — averaging $16.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Pfizer$1K
  • GSK$1K
  • AstraZeneca$1K
  • Lilly USA, LLC$705
  • Novartis$629
  • plus $6K from 54 others

What the payments were for

  • Food & beverage$13,183100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk150$1,998
Pfizer80$1,494
GSK89$1,483
AstraZeneca52$1,002
Lilly USA, LLC41$705
Novartis42$629
Boehringer Ingelheim37$598
Merck35$579
AbbVie(2 entities)30$521
Amarin Pharma, Inc.22$391
Abbott19$340
Johnson & Johnson20$338
Teva Pharmaceuticals USA, Inc.14$256
Sanofi-aventis U.S. LLC14$252
Exact Sciences10$243
Avanir Pharmaceuticals, Inc.14$208
Sunovion Pharmaceuticals Inc.10$141
Bayer8$129
Amgen7$123
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)6$121
Kowa Pharmaceuticals America, Inc.6$119
Abiomed2$106
E.r. Squibb & Sons, L.L.C.5$95
Phathom Pharmaceuticals, Inc.4$89
Neurelis, Inc.5$85
Shield Therapeutics Inc4$73
Astellas Pharma US Inc4$72
Biohaven Pharmaceuticals, Inc.4$72
Eisai Inc.4$63
Hikma Pharmaceuticals USA3$59
Otsuka America Pharmaceutical, Inc.3$58
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC3$56
Urovant Sciences Inc2$42
Dexcom, Inc.3$41
Ultragenyx Pharmaceutical Inc.2$37
Orexo US, Inc.2$35
Pulmonx Corporation2$35
Sumitomo Pharma America, Inc.2$31
SK Life Science, Inc.1$30
Alkermes, Inc.1$29
Paratek Pharmaceuticals, Inc.1$28
Aimmune Therapeutics, Inc.2$28
Neurocrine Biosciences, Inc.1$26
Evoke Pharma, Inc.1$25
Melinta Therapeutics, LLC1$25
IBSA Pharma Inc.1$25
Takeda Pharmaceuticals U.S.A., Inc.1$24
Nevro Corp.1$22
UCB, Inc.1$19
Boston Scientific1$19
Xeris Pharmaceuticals, Inc.1$18
Corcept Therapeutics1$18
Nestle Healthcare Nutrition Inc.1$18
Biohaven Pharmaceutical Holding Company Ltd.1$18
Daiichi Sankyo Inc.1$17
Almatica Pharma LLC1$17
Gilead1$16
Radius Health, Inc.1$16
RGH Enterprises LLC1$14
Monaghan Medical Corporation1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,189 in reported general payments places this provider in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$518,672
Medicare patients
483
Services billed
6,205

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,623$721,479
JardianceEmpagliflozin623$403,372
OzempicSemaglutide212$209,520
TradjentaLinagliptin310$204,684
EntrestoSacubitril/Valsartan297$198,948
Trelegy ElliptaFluticasone/Umeclidin/Vilanter305$195,920
TrulicityDulaglutide197$130,070
XareltoRivaroxaban174$87,202
JanuviaSitagliptin Phosphate114$70,784
Breo ElliptaFluticasone/Vilanterol163$68,706
Spiriva RespimatTiotropium Bromide118$67,607
BiktarvyBictegrav/Emtricit/Tenofov Ala12$50,959
NuplazidPimavanserin Tartrate19$46,724
FarxigaDapagliflozin Propanediol90$43,341
BrilintaTicagrelor85$40,292

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,494$721,4791,623 claims
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat, Stiolto Respimat$598$695,9491,096 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arexvy, Incruse Ellipta$1,483$341,338667 claims
Novo NordiskOzempic$1,998$209,520212 claims
NovartisEntresto$629$198,948297 claims
Lilly USA, LLCTrulicity, Mounjaro$705$165,878231 claims
Johnson & JohnsonXarelto, Invega Sustenna$338$117,190186 claims
AstraZenecaFarxiga, Brilinta$1,002$83,633175 claims
MerckJanuvia$579$70,784114 claims
GileadBiktarvy$16$50,95912 claims
AbbVieLinzess, Vraylar$521$42,76468 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$56$35,14818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →